Agent Orange as a risk factor for high-grade prostate cancer

Nathan Ansbaugh, Jackilen (Jackie) Shannon, Motomi (Tomi) Mori, Paige E. Farris, Mark Garzotto

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

BACKGROUND Agent Orange (AO) exposure (AOe) is a potential risk factor for the development of prostate cancer (PCa). However, it is unknown whether AOe specifically increases the risk of lethal PCa. The objective of this study was to determine the association between AOe and the risk of detecting high-grade PCa (HGPCa) (Gleason score ≥7) on biopsy in a US Veteran cohort. METHODS Risk factors included clinicodemographic and laboratory data from veterans who were referred for an initial prostate biopsy. Outcomes were defined as the presence versus the absence of PCa, HGPCa, or low-grade PCa (LGPCa) (Gleason score ≤6) in biopsy specimens. Risk among AOe veterans relative to unexposed veterans was estimated using multivariate logistic regression. Separate models were used to determine whether AOe was associated with an increased risk of PCa, HGPCa, or LGPCa. RESULTS Of 2720 veterans who underwent biopsy, PCa was diagnosed in 896 veterans (32.9%), and 459 veterans (16.9%) had HGPCa. AOe was associated with a 52% increase in the overall risk of detecting PCa (adjusted odds ratio, 1.52; 95% confidence interval, 1.07-2.13). AOe did not confer an increase in the risk of LGPCa (adjusted odds ratio, 1.24; 95% confidence interval, 0.81-1.91), although a 75% increase in the risk of HGPCa was observed (adjusted odds ratio, 1.75; 95% confidence interval, 1.12-2.74). AOe was associated with a 2.1-fold increase (95% confidence interval, 1.22-3.62; P

Original languageEnglish (US)
Pages (from-to)2399-2404
Number of pages6
JournalCancer
Volume119
Issue number13
DOIs
StatePublished - Jul 1 2013

Fingerprint

Veterans
Prostatic Neoplasms
Confidence Intervals
Biopsy
Neoplasm Grading
Odds Ratio
Agent Orange
Prostate
Logistic Models

Keywords

  • Agent Orange
  • prostatic neoplasms
  • risk factors
  • urology
  • veterans

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Agent Orange as a risk factor for high-grade prostate cancer. / Ansbaugh, Nathan; Shannon, Jackilen (Jackie); Mori, Motomi (Tomi); Farris, Paige E.; Garzotto, Mark.

In: Cancer, Vol. 119, No. 13, 01.07.2013, p. 2399-2404.

Research output: Contribution to journalArticle

Ansbaugh, Nathan ; Shannon, Jackilen (Jackie) ; Mori, Motomi (Tomi) ; Farris, Paige E. ; Garzotto, Mark. / Agent Orange as a risk factor for high-grade prostate cancer. In: Cancer. 2013 ; Vol. 119, No. 13. pp. 2399-2404.
@article{dd7204b1285b4f70a0aac01fb1fc280c,
title = "Agent Orange as a risk factor for high-grade prostate cancer",
abstract = "BACKGROUND Agent Orange (AO) exposure (AOe) is a potential risk factor for the development of prostate cancer (PCa). However, it is unknown whether AOe specifically increases the risk of lethal PCa. The objective of this study was to determine the association between AOe and the risk of detecting high-grade PCa (HGPCa) (Gleason score ≥7) on biopsy in a US Veteran cohort. METHODS Risk factors included clinicodemographic and laboratory data from veterans who were referred for an initial prostate biopsy. Outcomes were defined as the presence versus the absence of PCa, HGPCa, or low-grade PCa (LGPCa) (Gleason score ≤6) in biopsy specimens. Risk among AOe veterans relative to unexposed veterans was estimated using multivariate logistic regression. Separate models were used to determine whether AOe was associated with an increased risk of PCa, HGPCa, or LGPCa. RESULTS Of 2720 veterans who underwent biopsy, PCa was diagnosed in 896 veterans (32.9{\%}), and 459 veterans (16.9{\%}) had HGPCa. AOe was associated with a 52{\%} increase in the overall risk of detecting PCa (adjusted odds ratio, 1.52; 95{\%} confidence interval, 1.07-2.13). AOe did not confer an increase in the risk of LGPCa (adjusted odds ratio, 1.24; 95{\%} confidence interval, 0.81-1.91), although a 75{\%} increase in the risk of HGPCa was observed (adjusted odds ratio, 1.75; 95{\%} confidence interval, 1.12-2.74). AOe was associated with a 2.1-fold increase (95{\%} confidence interval, 1.22-3.62; P",
keywords = "Agent Orange, prostatic neoplasms, risk factors, urology, veterans",
author = "Nathan Ansbaugh and Shannon, {Jackilen (Jackie)} and Mori, {Motomi (Tomi)} and Farris, {Paige E.} and Mark Garzotto",
year = "2013",
month = "7",
day = "1",
doi = "10.1002/cncr.27941",
language = "English (US)",
volume = "119",
pages = "2399--2404",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "13",

}

TY - JOUR

T1 - Agent Orange as a risk factor for high-grade prostate cancer

AU - Ansbaugh, Nathan

AU - Shannon, Jackilen (Jackie)

AU - Mori, Motomi (Tomi)

AU - Farris, Paige E.

AU - Garzotto, Mark

PY - 2013/7/1

Y1 - 2013/7/1

N2 - BACKGROUND Agent Orange (AO) exposure (AOe) is a potential risk factor for the development of prostate cancer (PCa). However, it is unknown whether AOe specifically increases the risk of lethal PCa. The objective of this study was to determine the association between AOe and the risk of detecting high-grade PCa (HGPCa) (Gleason score ≥7) on biopsy in a US Veteran cohort. METHODS Risk factors included clinicodemographic and laboratory data from veterans who were referred for an initial prostate biopsy. Outcomes were defined as the presence versus the absence of PCa, HGPCa, or low-grade PCa (LGPCa) (Gleason score ≤6) in biopsy specimens. Risk among AOe veterans relative to unexposed veterans was estimated using multivariate logistic regression. Separate models were used to determine whether AOe was associated with an increased risk of PCa, HGPCa, or LGPCa. RESULTS Of 2720 veterans who underwent biopsy, PCa was diagnosed in 896 veterans (32.9%), and 459 veterans (16.9%) had HGPCa. AOe was associated with a 52% increase in the overall risk of detecting PCa (adjusted odds ratio, 1.52; 95% confidence interval, 1.07-2.13). AOe did not confer an increase in the risk of LGPCa (adjusted odds ratio, 1.24; 95% confidence interval, 0.81-1.91), although a 75% increase in the risk of HGPCa was observed (adjusted odds ratio, 1.75; 95% confidence interval, 1.12-2.74). AOe was associated with a 2.1-fold increase (95% confidence interval, 1.22-3.62; P

AB - BACKGROUND Agent Orange (AO) exposure (AOe) is a potential risk factor for the development of prostate cancer (PCa). However, it is unknown whether AOe specifically increases the risk of lethal PCa. The objective of this study was to determine the association between AOe and the risk of detecting high-grade PCa (HGPCa) (Gleason score ≥7) on biopsy in a US Veteran cohort. METHODS Risk factors included clinicodemographic and laboratory data from veterans who were referred for an initial prostate biopsy. Outcomes were defined as the presence versus the absence of PCa, HGPCa, or low-grade PCa (LGPCa) (Gleason score ≤6) in biopsy specimens. Risk among AOe veterans relative to unexposed veterans was estimated using multivariate logistic regression. Separate models were used to determine whether AOe was associated with an increased risk of PCa, HGPCa, or LGPCa. RESULTS Of 2720 veterans who underwent biopsy, PCa was diagnosed in 896 veterans (32.9%), and 459 veterans (16.9%) had HGPCa. AOe was associated with a 52% increase in the overall risk of detecting PCa (adjusted odds ratio, 1.52; 95% confidence interval, 1.07-2.13). AOe did not confer an increase in the risk of LGPCa (adjusted odds ratio, 1.24; 95% confidence interval, 0.81-1.91), although a 75% increase in the risk of HGPCa was observed (adjusted odds ratio, 1.75; 95% confidence interval, 1.12-2.74). AOe was associated with a 2.1-fold increase (95% confidence interval, 1.22-3.62; P

KW - Agent Orange

KW - prostatic neoplasms

KW - risk factors

KW - urology

KW - veterans

UR - http://www.scopus.com/inward/record.url?scp=84879102973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879102973&partnerID=8YFLogxK

U2 - 10.1002/cncr.27941

DO - 10.1002/cncr.27941

M3 - Article

VL - 119

SP - 2399

EP - 2404

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 13

ER -